Top Banner
Thomas F. Lüscher, MD, FRCP Professor of Cardiology, Imperial College and Director of Research, Education and Development, Royal Brompton and Harefield Hospital, London, UK Chairman, Center for Molecular Cardiology, University Zurich, Switzerland Covid-19 – in the End an Endothelial Disease Biomarkers & Personalized Medicine in Cardiology 2021
49

Covid-19 in the End an Endothelial Disease

Nov 21, 2021

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Covid-19 in the End an Endothelial Disease

Thomas F. Lüscher, MD, FRCP Professor of Cardiology, Imperial College and Director of Research, Education

and Development, Royal Brompton and Harefield Hospital, London, UK

Chairman, Center for Molecular Cardiology, University Zurich, Switzerland

Covid-19 – in the End an Endothelial Disease

Biomarkers & Personalized

Medicine in Cardiology

2021

Page 2: Covid-19 in the End an Endothelial Disease

1.Un (un-)expected Pandemic

2.A Lung Disease

3.Only a Lung Disease?

4.Covid-19 is in the end an Endothelial Disease

5.Covid-19 and Cardiac Injury and Disease

6.CV Collateral Damage of Covid-10

7.Post Covid Disease

Page 3: Covid-19 in the End an Endothelial Disease

On December 30th Dr. Li Wenliang warns of

a new Corona Virus causing Pneumonia

Page 4: Covid-19 in the End an Endothelial Disease
Page 5: Covid-19 in the End an Endothelial Disease

1.Un (un-)expected Pandemic

2.A Lung Disease

3.Only a Lung Disease?

4.Covid-19 is in the end an Endothelial Disease

5.Covid-19 and Cardiac Injury and Disease

6.CV Collateral Damage of Covid-10

7.Post Covid Disease

Page 6: Covid-19 in the End an Endothelial Disease

Lung CT Presentation of Covid-19

Typical Features: Multiple bilateral lobular and subsegmental areas of

groundglass opacity or consolidationa, crazy-paving pattern, air bronchograms,

reverse halo/perilobular pattern.

Atypical features: interlobular or septal thickening (smooth or irregular),

thickening of the adjacent pleura, subpleural involvement, pleural effu-sion,

pericardial effusion, bronchiectasis, cavitation, pneumothorax,

lymphadenopathy, round cystic changes.

Page 7: Covid-19 in the End an Endothelial Disease

Lin

Yan

g Eu

r. H

eart

J. 2

02

0

Page 8: Covid-19 in the End an Endothelial Disease
Page 9: Covid-19 in the End an Endothelial Disease

Endothelitis with Covid-19 at Autopsy

Varg

a et

al.

Lanc

et A

pril

17, 2

020

Page 10: Covid-19 in the End an Endothelial Disease

1.Un (un-)expected Pandemic

2.A Lung Disease

3.Only a Lung Disease?

4.Covid-19 is in the end an Endothelial Disease

5.Covid-19 and Cardiac Injury and Disease

6.CV Collateral Damage of Covid-10

7.Post Covid Disease

Page 11: Covid-19 in the End an Endothelial Disease
Page 12: Covid-19 in the End an Endothelial Disease

Interleukin-6 and serum Amyloid A levels at the site of coronary occlusion and in the

peripheral blood

Interleukin-1a Interleukin-1b

Inte

rleu

kin-

1 Inc

reas

e (%

)

Inte

rleu

kin-

6 (U

/ml)

Baseline Hypoxia

Reperfusion

Y. A

la e

t al.

Agen

ts &

Act

ion

1992

;37:

134-

138

Page 13: Covid-19 in the End an Endothelial Disease

Interleukin-6 and serum Amyloid A levels at the site of coronary occlusion and in the

peripheral blood

Page 14: Covid-19 in the End an Endothelial Disease

Thrombus and Cellular Inflammation at the Site of Plaque Rupture

Immunohistochemistry: CD68 Positive Macrophages (A), IL-6 Positive Staining (B)

Maier, Altwegg et al. Circulation 2005

Page 15: Covid-19 in the End an Endothelial Disease
Page 16: Covid-19 in the End an Endothelial Disease

TF VIIa

Prothrombin Thrombin

Fibrinogen Fibrin

VIIIa

IXa

XII XIIa

XI XIa

IX IXa

Xa X

Ste 2011

vWF

TXA2

ADP

GpIIb/IIIa

PAR-1

Thrombusbildung und Protektion

Aspirin?

Clopidogrel?

Prasugrel?

Ticagrelor?

Page 17: Covid-19 in the End an Endothelial Disease

TNF

(10 ng/mL,

6x10-10 mol/L)

NaCl

(5x10-2 mol/L)

LiCl

(5x10-2 mol/L)

- + + +

- - + -

- - - +

Tissue factor

Tumor Necrosis Factor induces Tissue Factor

in Human Endothelial Cells

47KDa

Western blotting

Eto and Lüscher Circulation 2005

Page 18: Covid-19 in the End an Endothelial Disease

H1

TNF-R

TLR-4 Il-1-R

Histamine

TNF-α

Il-1β

LPS

PAR

Thrombin

KDR

VEGF

CD40

CD40-L

Serotonin

5-HT2a

Inflammation begets Coagulation

TF-bearing

microparticles

asTF

TF pool

Cytoplasm Nucleus

Induction of Tissue Factor Expression

J. Steffel, T.F. Lüscher, F. C. Tanner. Circulation 2005

Page 19: Covid-19 in the End an Endothelial Disease

Eto et al. 2002

Prolonged Incubation with Thrombin

inhbits Endothelim-depedent Relaxations

Page 20: Covid-19 in the End an Endothelial Disease

eNOS

ECE-1

Thrombin (4U/ml, 24h) - + + -

C3 Exoenzyme - - + +

eNOS

ECE-1

Thrombin Regulates Endothelial NOS and ECE-1Expression:

Role of RhoA/ROCK Pathway

Eto et al. Circ. Res. 2001

Thrombin (4U/ml, 24h) - + + -

Y-27632 - - + +

Page 21: Covid-19 in the End an Endothelial Disease

C e l l M e m b r a n e

C y t o s o l

T h r o m b i n

R h o - G D P R h o - G T P

I n a c t i v e A c t i v e

R h o - K i n a s e

eNOS Expression

Tissue Factor

Y - 2 7 6 3 2

Thrombin and Rho/Rho-Kinase Pathway

Page 22: Covid-19 in the End an Endothelial Disease

Antivirals Cytokine inhibitors (IL-6, IL-1)

Corticosteroids

Page 23: Covid-19 in the End an Endothelial Disease
Page 24: Covid-19 in the End an Endothelial Disease
Page 25: Covid-19 in the End an Endothelial Disease
Page 26: Covid-19 in the End an Endothelial Disease
Page 27: Covid-19 in the End an Endothelial Disease
Page 28: Covid-19 in the End an Endothelial Disease

1.Un (un-)expected Pandemic

2.A Lung Disease

3.Only a Lung Disease?

4.Covid-19 is in the end an Endothelial Disease

5.Covid-19 and Cardiac Injury and Disease

6.CV Collateral Damage of Covid-10

7.Post Covid Disease

Page 29: Covid-19 in the End an Endothelial Disease

Myocardial Injury

• Myocarditis

• Heart Failure

• Hypoxia

• VTE or PE

Myocardial Ischemia

• NSTEMI

• STEMI

• Takotsubo

Cardiac Troponin and Outcome of Acute Covid-19 Infection

Page 30: Covid-19 in the End an Endothelial Disease
Page 31: Covid-19 in the End an Endothelial Disease
Page 32: Covid-19 in the End an Endothelial Disease
Page 33: Covid-19 in the End an Endothelial Disease
Page 34: Covid-19 in the End an Endothelial Disease
Page 35: Covid-19 in the End an Endothelial Disease

1.Un (un-)expected Pandemic

2.A Lung Disease

3.Only a Lung Disease?

4.Covid-19 is in the end an Endothelial Disease

5.Covid-19 and Cardiac Injury and Disease

6.CV Collateral Damage of Covid-10

7.Post Covid Disease

Page 36: Covid-19 in the End an Endothelial Disease
Page 37: Covid-19 in the End an Endothelial Disease

Admission for Myocardial Infarction During Covid-19 Pandemic in Italy Number of Patients admitted in the 12-19 March Week

Page 38: Covid-19 in the End an Endothelial Disease
Page 39: Covid-19 in the End an Endothelial Disease
Page 40: Covid-19 in the End an Endothelial Disease
Page 41: Covid-19 in the End an Endothelial Disease
Page 42: Covid-19 in the End an Endothelial Disease

Vascular Effects of Angiotensin 1-7

Page 43: Covid-19 in the End an Endothelial Disease
Page 44: Covid-19 in the End an Endothelial Disease
Page 45: Covid-19 in the End an Endothelial Disease
Page 46: Covid-19 in the End an Endothelial Disease

1.Un (un-)expected Pandemic

2.A Lung Disease

3.Only a Lung Disease?

4.Covid-19 is in the end an Endothelial Disease

5.Covid-19 and Cardiac Injury and Disease

6.CV Collateral Damage of Covid-10

7.Post Covid Disease

Page 47: Covid-19 in the End an Endothelial Disease
Page 48: Covid-19 in the End an Endothelial Disease
Page 49: Covid-19 in the End an Endothelial Disease

Many thanks for your attention!